PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.

Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. · 2016

Read PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. by Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5078108.txt.

Introduction

Xiaoman Li and seven co-authors review a growth signaling pathway and its drug targeting in glioblastoma, in Oncotarget in 2016. Glioblastoma is the most common and aggressive brain tumor, with five-year survival under five percent; standard care is radiation plus one chemotherapy drug. Its growth factor receptor EGFR is often overproduced or mutated, switching on the PI3K/Akt/mTOR pathway that drives growth and blunts chemotherapy.

Genetic changes hitting this pathway appear in most glioblastomas, and patients whose pathway is active fare worse. The review explains why blocking the pathway is an attractive strategy and gathers the trial record for EGFR and pathway inhibitors so far. Results have disappointed: cross-talk between pathways and tumor variety undercut single-target drugs. The authors look instead to combinations of targets and treatment matched to each patient's tumor, and they note early work pairing pathway drugs with other agents.

Catalog record

CREATORLi X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5078108

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma By Xiaoman Li, Changjing Wu, Nianci Chen, Huadi Gu, Allen Yen, Liu Cao, Enhua Wang, Liang Wang Published in: Oncotarget DOI: 10.18632/oncotarget.7961 ABSTRACT Abstract Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials. Keywords: glioblastoma, EGFR, PI3K/Akt/mTOR pathway, targeted therapy INTRODUCTION Glioblastoma multiform Glioblastoma multiform (GBM), WHO grade IV, is the most common and aggressive glioma of all primary brain tumors, exhibiting a high rate of recurrence and poor prognosis due to the invasive nature of the tumor [1, 2]. Considering the location and diffusely infiltrating nature of the tumor, complete surgical resections are challenging. Standard therapy for GBM is radiation plus the chemopeutic agent temozolomide (TMZ). The cytotoxicity of TMZ is thought to be primarily due to alkylation of DNA hence leading to DNA damage and tumor cell death [3]. However, the activation of PI3K/Akt/mTOR pathway leads to the development of drug resistance thereby dampening the therapeutic effect of TMZ [4]. The five year survival rate for glioblastoma is less than 5% in adults [5-7]. The occurrence of GBM is frequently associated with molecular changes in epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathways. The frequency of genetic alterations such as overexpression EGFR, activating mutations of PI3CA (p110) or PIK3R1 (P85), or loss of PTEN expression has been estimated to around 88% [8-12]. GBM patients with an activated PI3K/Akt/mTOR pathway also have poor prognosis than patients without oncogenic activation of the pathway [13]. Therefore, inhibitors targeting EGFR and PI3K/Akt/mTOR pathway have emerged as potential treatment for GBM [14-18]. Currently, a series of inhibitors targeting EGFR and PI3K/Akt/mTOR pathway are evaluated in preclinical and clinical studies as single agent or in combination with the traditional treatment [19]. It is of particular interest to explore whether those inhibitors are effective to restore the therapeutic sensitivity. EGFR and PI3K/Akt/mTOR signal transduction pathway EGFR is a type of receptor tyrosine kinases (RTKs), playing a central role in cell division, migration, adhesion, differentiation and apoptosis [20, 21]. EGFR comprises of extracellular ligand binding domain, transmembrane domain and intracellular tyrosine kinase domain. Upon binding to various of ligands, such as EGF and TGFα, EGFR is activated through homodimerization or heterdimerization on the cell surface and subsequently leads to the phosphorylation of its intracellular tyrosine kinase domain [22]. The activation of EGFR results in activation of multiple downstream signal transduction pathways such as PI3K/Akt/mTOR pathway [23]. Members of the PI3K family are lipid kinases involved in multiple cellular process, including proliferation, differentiation, migration, metabolism and survival [24]. PI3K is generally classified into three classes according to their substrate specificity and subsequence homology, among which, the class I is most vital to the tumorigenesis. Class I consisted of a catalytic subunit p110 (α, β, γ) and a regulator subunit p85. A fourth p110 isoform (p110δ) is paired with the p101 regulatory subunit in class IB PI3Ks. Upon ligand binding, phosphorylated tyrosine residing in activated RTKs will bind to p85. The subsequent conformation change will release the catalytic subunit p110 [25], where activated p110 phosphorylated the phosphatidy-linositol-3, 4-bisphosphate (PIP2) into the second messenger phosphatidylinositol-3, 4, 5-bisphosphate (PIP3). This reaction can be reversed by the PI3K antagonist PTEN (phosphatase and tensin homolog deleted on chromosome ten) [26]. Subsequently, PIP3 will recruit the downstream Akt to inner membranes and phosphorylates Akt on its serine/threonine kinasesites (Thr308 and Ser473) [27, 28]. Activated Akt is involved in the downstream mTORC1 mediated response to biogenesis of protein and ribosome. In PI3K pathway, mTOR acts as both a downstream effector and an upstream regulator [29, 30]. mTOR resides in rapamycin-sensitive mTOR-complex (mTORC1) and a rapamycin-insensitive complex (mTORC2) [31, 32]. The activated Akt inhibits tuberous sclerosis complex (TSC) 1/2 activity, thereby initiate the mTORC1-mediate signaling pathway, involving in the phosphorylation of ribosomal protein S6 kinase (pS6k), eukaryotic initiation factor 4E (eIF4E) and eukaryotic initiation factor binding protein 1(4EBP1), which participate in protein translation, ribosome biogenesis as well as cell growth [33, 34]. The mTORC2 phosphorylates Akt at Ser-473, and then further takes part in cell survival, metabolism, proliferation, and cytoskeletal organization [31, 35]. Within PI3K signaling pathway, another important molecule is PTEN. As clinical research revealed, the EGFR or PTEN mutation would lead to continuous activation of PI3K/Akt/mTOR signaling pathway, thereby contributing to the tumorigenesis and cancer therapy resistance (Figure 1). [Figure: Schematic representation of the PI3K/Akt/mTOR signaling pathwayUpon relevant ligand binding, RTK, such as EGFR, is activated and subsequently inducing a series of cascade reaction. First, the regulator subunits of PI3K, p85, dimerize and release its catalytic subunit p110. p110 enables the membrane protein PIP2 to phosphorylate into PIP3. PIP3 begins to recruit the downstream Akt to inner membranes and phosphorylated the serine/threonine kinase (Thr308 and Ser473) sites by phosphoinositide-dependent kinase 1/2 (PDK1/2). Activated Akt is involved in the downstream mTORC1 mediated response to biogenesis of protein and ribosome. Besides that, activated Akt is also involved in the regulation of cell cycle and pro-apoptotic and anti-apoptotic factors mediated choices of cell apoptosis and survival. Additionally, it is also involved in the NFκB/MDR1 mediated drug resistance.] THE DEVELOPMENT OF TARGETED THERAPY TOWARDS EGFR AND PI3K/AKT/MTOR EGFR inhibitors EGFR alteration, including overexpression or gene amplification, is the most frequent form of genetic mutation, occurred in 40-50% of glioblastomas [36, 37]. Logically, EGFR is a promising target for the treatment of GBM. Though promising results was shown in preclinical data, targeting EGFR in clinical trials revealed marginal effects. An overview of ongoing clinical trial in GBM is summarized in Table 1. Information about clinical trials has been retrieved from www.clinicaltrials.gov. In the clinical trial NCT00250887, the effectiveness of EGFR tyrosine kinase inhibitor Gefitinib was tested in recurrent glioblastoma. Though EGFR was successfully -dephosphorylated, the downstream target remains constitutively active. Therefore the effectiveness was unsatisfactory [38]. Erlotinib, another selective EGFR inhibitor, also showed minimal effect to treat the recurrent glioblastoma (NCT00086879) [39]. Other than single agent treatment, combination therapy was also explored. When Erlotinib was combined with TMZ and radiotherapy in a phase I/II trial, no sign of benefit was showed compared with TMZ controls (NCT00039494) [40, 41]. Additionally, the combination therapy of Erlotinib with VEGF antibody also shows no obvious survival benefit [42]. The failure of targeting EGFR is generally due to the hyperactivation of downstream PI3K/Akt signaling, so the downstream components represents an attractive target for the treatment of malignant brain tumors. [Table: Ongoing clinical trials in brain tumors targeting EGFR] PI3K inhibitors Currently, the PI3K inhibitors as a single agent or combined with other therapies are being tested in a number of clinical trials (Table 2) [43]. There are pan-PI3K inhibitors and isoform specific PI3K inhibitors [14]. The first generation of pan-PI3K inhibitors is represented by wortmannin and LY294002 [44, 45]. They have showed anti-cancer

Read the complete text